Introduction to colorectal cancer genetics

Milestones in the genetic characterization of colorectal cancer
Cancer, colorectal cancer (CRC) included, is a disease marked by the aberrant behavior of cells that invade and destruct pre-existing tissues, both locally in the organ of origin and at a distance, i.e., metastatic sites. This selfish cell growth, and altered metabolic processes associated with it, can be lethal, despite of medical interventions. The aberrant behavior of tumor cells is driven by alterations in cell biology and affects critical processes such as proliferation, invasion, evasion to cellular death, and escape to immune surveillance, i.e., the so-called hallmarks of cancer (Hanahan and Weinberg, 2011) . These alterations in cell biology, in turn, are the result of an evolutionary process by which gene mutations and somatically acquired copy number alterations (CNAs) accumulate and result in the selective advantage of cells that carry these alterations. The accumulation of genetic damage results in the expansion of initially benign (i.e., non-invasive) tumors, which, when untreated, form invasive subclones and lead to cancer. DNA alterations come in many flavors, namely, small nucleotide variants (SNVs), small insertions or deletions (Indels), structural variants (SVs) or epigenetic alterations, mostly promoter hypermethylation, and in chromosomal copy number alterations, i.e., aneuploidy. The role of chromosomal aneuploidy in tumorigenesis was for a long time underestimated despite observations by Hansemann in the 19th century (Hansemann, 1890) , and work by Theodor Boveri in the 1920s https://doi.org/10. 1016 /j.mam.2019 .07.007 Received 19 March 2019  Received in revised form 23 July 2019; Accepted 26 July 2019 (reviewed in Ried, 2009 ). In fact, in several hematological neoplasia and soft tissue tumors, specific chromosomal rearrangements had been found to be pathogenic (Rabbitts, 1994) . Karyotyping of metaphases from tumor cells had been key to these observations, and this approach worked well in leukemias and soft tissue tumors, describing single or few chromosome rearrangements resulting in fusion genes (Heim and Mitelman, 2015) . However, the role of specific chromosomal changes in the origin of solid tumors like CRC was harder to establish, mainly attributable to very complex and highly rearranged karyotypes. Yet, using methods like DNA flow cytometry and DNA image cytometry it had been clearly established that most CRCs showed abnormal nuclear DNA content, for which chromosomal copy number changes can be the only explanation (Giaretti et al., 2004; Steinbeck et al., 1994 Steinbeck et al., , 1993 .
Groundbreaking work from Vogelstein and collaborators early in the 90's has shown that the accumulation of alterations in genes involved in key signaling pathways led to the neoplastic alteration of normal colonic epithelial cells, ultimately transforming into cancer (Fearon and Vogelstein, 1990) . Accordingly, an early crucial event in the development of CRC is the disruption of the WNT-signaling pathway, leading to the formation of an adenoma, and this occurs in the majority of cases by disruption of the APC gene, either by truncating mutations or, less frequently, by loss of the long arm of chromosome 5 (5q), where APC is located. Subsequent accumulation of mutations in KRAS involved in the MAPK signaling pathway, losses on the long arm of chromosome 18, affecting TGF-β signaling pathway, and mutations in TP53 or loss of the short arm of chromosome 17 (17p), where TP53 is located, result in the formation of cancer (Fearon and Vogelstein, 1990) .
With the introduction of comparative genomic hybridization (CGH) Kallioniemi et al., 1992) and, later on, microarray CGH (array CGH) (Pinkel et al., 1998) , it became possible to analyze CNAs genome-wide in one single experiment without the need for metaphase chromosome preparations from dividing cells. These molecular cytogenetic analyses confirmed and refined results established using conventional karyotype analysis (Bardi et al., 1993 (Bardi et al., , 1991 . This led to thorough characterization of non-random CNAs observed in microsatellite stable CRC, mainly gains of chromosomes 7, 8q, 13, and 20q as well as losses of 8p, 17p, and 18 (Camps et al., 2006; Douglas et al., 2004; Meijer et al., 1998; Nakao et al., 2004; Ried et al., 1996) Together with SNVs and CNAs, other alterations at the DNA or epigenome level turned out to be important as well. CpG island promoter methylation is a relevant mechanism for silencing gene expression (Baylin and Herman, 2000) and it is suggested to precede CNAs in the development of some CRC (Derks et al., 2006) . In 2012, The Cancer Genome Atlas Network (TCGA) comprehensively characterized 276 CRCs at mutation, DNA copy number, hypermethylation and expression levels (Cancer Genome Atlas Network, 2012). They confirmed previously well-defined CNAs, including 1q, 7, 8q, 13q, and 20q gains and 1p, 4, 5q, 8p, 14q, 15q, 17p , and 18q losses as being frequently observed in CRC. These CNAs frequently co-occur within the same tumor, indicating potential interaction between loci within these chromosomes leading to a selective advantage (Hermsen et al., 2002; Takahashi et al., 2015) .
Patho-biological classification of colorectal cancer
There are many ways in which CRCs can be patho-biologically classified. Two main genomic instability pathways are observed in CRC, the chromosomal instability (CIN) pathway, occurring in 85% of the cases, and the microsatellite instability (MSI) pathway, occurring in 15% of the cases (Lengauer et al., 1998) . CIN CRCs are characterized by gross chromosomal aberrations (numerical and structural) while MSI CRCs are characterized by mutations at single nucleotide level in repetitive regions (microsatellites) resulting from a deficiency in the DNA mismatch repair mechanism (Boland and Goel, 2010) .
CRCs can also be classified according to the levels of promoter hypermethylation (CpG Island Methylator Phenotype; CIMP), being divided in CIMP-high and CIMP-low CRCs (Toyota et al., 1999) . There is a strong association of MSI phenotype with CIMP, due to hypermethylation of the mismatch repair gene hMLH1 (Cancer Genome Atlas Network, 2012) . Another classification based on the transcriptome has been put forward, including four different subtypes of CRC (Guinney et al., 2015) . These Consensus Molecular Subtypes (CMS), however, are not completely discrete classes as there is some degree of overlap, reflecting a continuity of CRC transcriptomes . With the exception of CMS1 (MSI CRCs), all other 3 CMS groups (CMS2-4) present to a certain extent higher/lower degree of CNAs (CIN CRCs) (Guinney et al., 2015) . Translation of CMS classification to preclinical models and clinical practice uncovered potential for targeted treatment (Sveen et al., 2018) .
Temporal acquisition of CNAs throughout colorectal tumorigenesis
Adenoma to carcinoma progression
The disruption of the WNT-signaling pathway and the acquisition of chromosomal aneuploidy (e.g., extra copy of chromosome 7) might result in the formation of an adenoma, which progresses towards carcinoma through the accumulation of additional (epi)-genetic alterations in a background of genomic instability (Fearon and Vogelstein, 1990) . Different precursor lesions, with different morphology, can lead to the development of CRC. These can be conventional (polypoid or flat) adenomas or sessile serrated polyps. Although the total amount of CNAs in advanced adenomas is low compared to carcinomas, the presence of chromosomal aneuploidies and genomic alterations in such premalignant lesions needs to be considered, contributing to the acquisition of relatively high levels of genetic heterogeneity (Cross et al., 2018) . Furthermore, differences in the patterns of CNAs can be observed between different morphologies, namely, polypoid adenomas and non-polypoid adenomas. In a comparison of a large series of nonpolypoid adenomas with polypoid adenomas, it was shown that nonpolypoid adenomas more frequently presented 5q losses, but less 1p, 10q, 17p and 18q losses than polypoid adenomas (Voorham et al., 2012) . Other precursors, such as sessile serrated polyps (IJspeert et al., 2015) , progress to cancer via the MSI pathway, and therefore do not show the common CNAs observed in tumors arising via the CIN pathway (Bettington et al., 2017; Casorzo et al., 2015; Gaiser et al., 2013) .
DNA copy number alterations associated with progression
Despite the fact that chromosomal aneuploidies can be observed in premalignant lesions, their appearance is more frequent in later stages during the transition to malignancy (Matano et al., 2015; Saito et al., 2018) . Several studies showed that specific CNAs were associated with such transition (Hermsen et al., 2002; Meijer et al., 1998; Ried et al., 1996) . It has been demonstrated that in adenomas in which a carcinoma is present (so-called progressed adenomas), the phenotypically benign part already contains most chromosomal aberrations present in the cancer, indicating a role of these aberrations, namely gains of 8q, 13q and 20q, and losses of 8p, 15q, 17p and 18q, in the adenoma-tocarcinoma progression Hermsen et al., 2002) (Fig. 1) . The presence of two or more of these CNAs has an accuracy of 80% for predicting the risk of an adenoma to progress to cancer (Hermsen et al., 2002) . Moreover, studies modelling colorectal adenoma-to-carcinoma progression by perturbing organoids with gene mutations have shown that only organoids derived from adenomas with CNAs were able to form invasive tumors in mice, indicating the importance of these alterations (Drost et al., 2015; Matano et al., 2015) . Genomic imbalances in distant metastases (e.g., liver) are of high similarity as those already present in the adenocarcinoma (Haan et al., 2014; Platzer et al., 2002; Xie et al., 2014) . Altogether, these studies show the significance of CNAs with respect to the progression from colorectal adenomas to cancer.
High-risk adenoma versus advanced adenoma
Colorectal adenomas are a very common finding in elderly people with a prevalence of 18-35% reported in screening series (Imperiale et al., 2000; Lieberman et al., 2000) . However, it is thought that only about 5% of colonic polyps removed at the time of endoscopy would have progressed to cancer (Shinya and Wolff, 1979) . Indeed, histopathological features associated with the presence of focal cancer in adenomas include size ≥10 mm, high-grade dysplasia and villous histology (Muto et al., 1975; Shinya and Wolff, 1979) . The presence of at least one of these histopathological features led to the concept of advanced adenoma (Winawer et al., 1993) . However, the accuracy of these features to identify advanced adenomas that would be at risk to progress to cancer is low. Nonetheless, advanced adenomas are used in screening and surveillance programs as intermediate endpoints for CRC death. In a study evaluating the long-term effect of adenoma removal on reduction of CRC mortality, only a moderate effect was observed when advanced adenomas were removed (Løberg et al., 2014) . This indicates that the use of advanced adenomas as intermediate endpoints associated with disease progression, leads to an overestimation of risk of dying from CRC, which translates to overdiagnosis. There is need for new intermediate endpoints that more precisely reflect the natural course of the disease, and more specifically identify adenomas at high risk of progressing to cancer (Sillars-Hardebol et al., 2012) . In a recent pilot study, it has been shown that only 25% of advanced adenomas showed DNA CNAs associated with progression and that 2-4% of nonadvanced adenomas already show these aberrations . This indicates that CNAs associated with progression from adenoma to cancer could more accurately identify adenomas at risk and therefore perform better as intermediate endpoints in CRC screening and surveillance programs.
Comprehensive assessment of copy number alterations
Experimental strategies to analyze copy number alterations in cancer
Beyond conventional G-banding, molecular cytogenetic techniques, including FISH-related approaches (Cremer et al., 1988 (Cremer et al., , 1986 Pinkel et al., 1988; Ried et al., 1992; Schröck et al., 1996; Speicher et al., 1996) and conventional and array CGH Kallioniemi et al., 1992 Kallioniemi et al., , 1992 Pinkel et al., 1998) , improved the analysis of chromosome aberrations in both hematological and solid tumors. CGH allowed mapping of genomic imbalances in solid tumors to an unprecedented level by comparing the genomic DNA extracted from the tumor sample with a reference genome without the requirement of metaphase chromosome preparations. This allowed the use of formalin-fixed and paraffin embedded material for cytogenetic analyses (Ried et al., 1995; Speicher et al., 1993) . The application of CGH provided evidence that genomic imbalances were responsible for tumor progression from dysplastic lesions to invasive disease . Later on, single nucleotide polymorphism (SNP)-based DNA microarrays allowed simultaneous measurement of the allelespecific copy number at many different single nucleotide polymorphic loci in the genome, thus resulting in a high resolution detection of LOH, a common event in tumorigenesis, in addition to the identification of CNAs at a resolution similar to that of array CGH (Beroukhim et al., 2006; Heinrichs and Look, 2007; Mullighan et al., 2007) . This technology also allowed the identification of copy neutral LOH, a common feature affecting cancer, including colorectal (Torabi et al., 2019 (Torabi et al., , 2015 Tuna et al., 2009 ).
Novel methodologies to assess copy number alterations based on nextgeneration sequencing
Besides array CGH and SNP-arrays, the development of massive parallel sequencing through next-generation sequencing platforms led to the development of many tools to infer CNAs from whole-exome (WES) and whole-genome sequencing (WGS). Consensus "best-practices" workflow for short-reads sequencing management has been possible, in part, due to the Genome Analysis Toolkit (GATK) (McKenna et al., 2010) . In addition, many other calling tools have been included in the omicX database (https://omictools.com) (Henry et al., 2014) , some of the most relevant being listed in Table 1 . Four computational approaches to handle genomic sequencing have been described to detect structural variants of the genome: (i) read pair, which compares distances between mapped paired reads and average insert size of the genomic library; (ii) split read, to detect small insertions and deletions through analyzing alignment to the reference genome, taking special attention to continuous stretches of gaps in the reads; (iii) assembly methods, where reference-free reconstruction of the entire genome from a collection of reads is computed and compared to the reference genome by applying multiple software; and (iv) read count or depth of coverage, the most recent approach, which takes into account the number of reads mapping for each region in the genome and assuming uniform sequencing process, so the number of reads in a specific region would be proportional to its copy number (Magi et al., 2017; Yoon et al., 2009 ). Recent studies have attempted to benchmark and evaluate the performance of several methods, further emphasizing differences Fig. 1 . Genomic alterations associated with the histopathological sequence of colorectal tumorigenesis. As shown, while APC mutation is present in most lowgrade adenomas, chromosomal aneuploidies affecting chromosomes 7, 13 and 20q occur prior the transition from adenoma to adenocarcinoma. As indicated, additional genomic imbalances and single nucleotide variants result in the formation of the infiltrating adenocarcinoma providing the invasive phenotype. Histological sections are representative images stained with hematoxylin and eosin.
T. Ried, et al. Molecular Aspects of Medicine 69 (2019) 48-61 between tools despite the common usage of a calling method for data segmentation (Alkodsi et al., 2015; Kadalayil et al., 2015; Liu et al., 2013; Nam et al., 2016; Trost et al., 2018; Zare et al., 2017) . Tools such as GISTIC2.0 (Mermel et al., 2011) , ConVaQ (Larsen et al., 2018) or CNApp (Franch-Exposito et al., 2018) allow cohort-level studies to integrate genomic CNA data with additional molecular and clinical features, and unravel new functional implications for these genomic events.
Copy number alteration signatures
To a certain extent, cancer genome SNVs and CNAs delineate the track of unrepaired genetic alterations that have accumulated during the lifetime of the tumor. In this sense, studies of SNV signatures identified mutational patterns originated by different types of nucleotide changes in a given tumor type, defined as mutational signatures (Alexandrov et al., 2013; Nesic et al., 2018) . In contrast to SNVs, only the calling for the presence or absence of a chromosome alteration in tumor cells, but not the underlying mechanisms of such patterns, are described. Therefore, efforts to identify copy number signatures have been made considering different approaches and accounting for diverse features. By applying non-negative matrix factorization models to 32 rearrangement subclasses in whole genome sequencing derived breast cancer data, six rearrangement signatures based on their association with homologous recombination deficiency and microhomology-mediated end joining mechanisms were extracted (Nik-Zainal et al., 2016) . Likewise, eight copy number signatures based on structural features obtained from copy number profiles were identified by using low-pass whole genome sequencing in high-grade serous ovarian cancer (Macintyre et al., 2018) . These authors correlated CNA signatures with prognosis and response to treatment, suggesting their utility as clinical biomarkers. Finally, pan-cancer studies unraveled nine signatures responsible for the etiology of structural variants, suggesting that replication-based mechanisms generated varying chromosomal structures with low-level copy number gains and frequent inverted rearrangements across different tumor types, including CRC (Camps et al., 2008; Li et al., 2017) .
Transcriptional consequences of copy number alterations
Positive correlation between copy number alterations and expression levels
It has been firmly established that CNAs are specific to the tissue of cancer origin, thus reflecting specific landscapes of genomic imbalances for each tumor type (Beroukhim et al., 2010; Ried et al., 2012) . As mentioned earlier, in colorectal carcinomas, tumorigenesis requires specific CNAs, e.g., gains of chromosomes 7, 8q, 13, and 20q, and losses of 8p, 17p, and 18. Such observations trigger the question what are the consequences of these so dominantly selected aneuploidies with respect to the transcription levels of genes on the affected chromosomes. In fact, among several hypotheses as to why transcriptional programs are affected by arm-level and whole chromosome-level CNAs, the body of literature indicates that CNAs directly affect the expression of the majority of genes on the altered genomic segment; however, the extent to which genes other than oncogenes and tumor suppressors contribute to malignant transformation or maintenance of the transformed state remains unclear. The biological consequence of chromosomal aneuploidy is not limited to the affected chromosomal region, but may be due to effects on the transcriptional activity of genes residing in other areas of the genome. Naturally, a third possibility is that chromosomal aneuploidies only target a small or limited number of genes conferring a selective advantage for the metabolism of the cancer cell.
Cell lines derived from primary carcinomas have been extensively used to measure the effect of genomic CNAs on the expression of resident genes. Analysis of 15 CRC cell lines, including mismatch repair proficient and deficient lines, showed positive genome-wide correlation between CNAs determined by array CGH and corresponding average gene expression (Camps et al., 2009 ). Such correlations have been confirmed in many other tumor types. For example, Wolf and colleagues arrived at the conclusion that a correlation between copy number with gene expression levels became evident genome-wide in prostate cancer cell lines (Wolf et al., 2004) . Using the NCI-60 cancer cell line panel, a correlation between gene expression and copy number for all genes showed an overall medium high correlation, with significantly higher correlations for the known tumor suppressor genes (Varma et al., 2014) . Recently, Tao and colleagues reported that gene up-regulation or down-regulation is significantly correlated with genomic amplification or deletion events in a set of six cervical cancer cell lines (Yan et al., 2017) .
The correlation of genomic copy number and average gene expression levels also applies to primary tumors. In fact, several authors have shown the influence of canonical arm and chromosome-level CNAs on gene expression levels in pre-malignant lesions and carcinomas of different origin (Camps et al., 2008; Carvalho et al., 2009; Fehrmann et al., 2015; Grade et al., 2007 Grade et al., , 2006 Ortiz-Estevez et al., 2011; Pollack et al., 2002) (Fig. 2 ). In this set of studies, the authors have explored several cohorts of colon and rectal cancer samples and matched normal mucosa, and identified that upregulation of genes was highest for those located on chromosomes 7, 13 and 20, i.e., chromosomes that are consistently gained, while downregulated genes were consistently located at chromosome 18, and to a lesser extent, at WES, whole-exome sequencing; WGS, whole-genome sequencing.
T. Ried, et al. Molecular Aspects of Medicine 69 (2019) 48-61 chromosomes 14 and 15, which are usually lost in CRC. By assessing the expression levels of normal colon epithelium, adenomas, carcinomas of different stages, and metastasis two independent studies provided further evidence of a copy number dependent transcriptional deregulation (Habermann et al., 2007; Tsafrir et al., 2006) . Additionally, Sheffer and colleagues convincingly demonstrated that the pattern of gene expression profiles alone is sufficient to predict genomic CNAs in a comprehensive dataset of colorectal carcinomas (Sheffer et al., 2009 ). Recently, data derived from whole-genome sequencing and reported by The Cancer Genome Atlas consortium was used to map somatic structural changes, including CNAs, in 600 tumors of diverse origins, showing their contribution to altered gene expression in human cancer (Alaei-Mahabadi et al., 2016) . A gene-oriented assessment of such positive correlation between CNAs and gene expression has resulted in the discovery of novel cancerrelated genes. In particular, in CRC, the gain of chromosome 13 and their associated overexpression of numerous genes, provided a unique chance to uncover several genes associated with tumorigenesis. Notably, these gene-dosage transcriptional dependent genes were mostly located at the proximal cytoband 13q12.12-q12.2. This included CDK8, CDX2, and LNX2, for which the overexpression was associated with WNT-pathway activity and tumorigenic features Firestein et al., 2008; Salari et al., 2012) . Similarly, but in a more distal region of the same chromosome, DIS3, KLF5, IRS2, and miRNA family miR17-92 were also chromosome 13 located cancer-related genes (Camps et al., 2003; Day et al., 2013; de Groen et al., 2014; Diosdado et al., 2009; Le et al., 2015) . Besides overexpression of genes on chromosomes usually involved in recurrent CNAs, other regions of CRC genomes eventually involved in genomic imbalances do as well contain genes whose expression is correlated with gene dosage, such as the amplification and consequent overexpression of IGF2 at 11p15.1 (Cancer Genome Atlas Network, 2012). Furthermore, an amplicon present in > 70% of colorectal tumor samples at 20q11-20q13 contained several cancer-related genes (AHCY, POFUT1, RPN2, TH1L, and PRPF6) that were upregulated and showed a significant linear correlation for gene dosage and gene expression (Loo et al., 2013) . Also, TPX2 (20q11.21) and AURKA (20q13.2), overexpressed as a consequence of gene-dosage, were shown to play a functional role as oncogenes driving this amplicon (Sillars-Hardebol et al., 2012) . Similarly, copy number loss at 8p, a CNA associated with colorectal adenocarcinoma and poor prognosis, was observed in > 50% of the tumor samples and demonstrated a significant linear correlation for two potential tumor suppressor genes, MTUS1 (8p22) and PPP2CB (8p12) (Loo et al., 2013) . Additionally, focal deletions at 6q25-q27 reducing the expression of PARK2 have been associated with APC deficiency in CRC (Poulogiannis et al., 2010b) . Other integrative studies in CRC revealed that the genes ARGLU1, UGGT2, CES2, FUT10, and PAOX were the top five correlated genes in a set of 15 paired tumor-normal samples (Ali Hassan et al., 2014) .
Model systems to study aneuploidy-dependent changes in the transcriptome
In order to study the impact of CNAs on gene expression, several cell line or animal models have been developed. Despite the technical difficulties on generating stable models of aneuploidy, several groups have addressed the physiological and functional effects of aneuploidy-dependent transcriptional deregulation in model systems, such as cell lines (Habermann et al., 2007; Nawata et al., 2011; Stingele et al., 2012; Upender et al., 2004; Wangsa et al., 2019) , budding yeast (Torres et al., 2007) , and mouse models (Williams et al., 2008) . These and other studies have further revealed that CNAs affect the expression not only of the genes located on the aneuploid chromosome, but also of multiple other genes across the entire genome, which influence protein expression as well (Gemoll et al., 2013; Sheltzer et al., 2012) . This massive transcriptional deregulation triggers cellular pathways associated with environmental stress response, which at least in yeast, seems to be related to the aneuploidy-driven slow growth (Donnelly and Storchová, 2014; Torres et al., 2007) . In addition, cellular responses similar to those observed in artificially induced trisomic cells are related to proteotoxic stress, most likely due to the increased amount of the protein load in the cell, which may induce autophagy (Chunduri and Storchová, 2019) . Furthermore, at the physiological level several model systems have suggested compromised growth as a consequence of induced aneuploidy, leading to the hypothesis that single-chromosome gains can suppress transformation in newly generated trisomies; however, after cellular progression and associated genome destabilization, the same study showed that evolved complex karyotypes contributed to the aggressive growth of advanced malignancies (Sheltzer et al., 2017) .
CNAs as biomarkers for clinical outcome
Association of CNAs with clinical-histological features and outcome
Only a few genetic biomarkers are currently used in clinical decisions related to CRC. These include RAS mutation, which is used routinely in CRC patients to guide the administration of anti-EGFR therapy. Similarly, the BRAF V600E mutation is a biomarker of poor prognosis in Upender et al., 2004) . Positive correlation between array CGH and gene expression for genes on chromosome 7 has been established for a set of 18 patients with colorectal cancer (R = 0.949) (right panel) (data source from Camps et al., 2013) . (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) T. Ried, et al. Molecular Aspects of Medicine 69 (2019) 48-61 In the CAPIRI therapy cohort, gain of this region was associated with a shorter PFS (p = 0.047) Haan et al. (2014) 5q12.1-q12.3
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In the CAP therapy cohort, loss of this region was associated with a shorter PFS (p = < 0.001) Haan et al. (2014) 5q34 Loss CCNG1 133
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Patients having EGFR CN gain achieved a high percentage of partial remission (p = 0.02), while those patients without EGFR CN gain had progressive disease (p = 0.001). Furthermore, patients having high EGFR copy number had a longer TTP (p = 0.04) Scartozzi et al. (2009) 7q22.1
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Significantly associated with tumor perforation (p = 0.001) and later T stage (p = 0.048) Lee et al. (2018) 7q31.2
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MET amplification associated with cetuximab-resistance in patients that are wildtype for KRAS, BRAF, NRAS, PIK3CA, and HER2. (p = 0.006) Bardelli et al. (2013) 12p12.3
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Patients having STRAP amplification and not receiving 5-FU/MMC adjuvant chemotherapy have a better prognosis (HR = 0.26, p = 0.004). Patients having the amplification and receiving 5-FU/MMC adjuvant therapy have a worse prognosis (HR = 3.48, p = 0.019) Buess et al. (2004a) 17q21-q21.3
Loss PSMB3, PIP4K2B, CCDC49, RPL23, LASP1, RPL19, FBXL20, MED1, CRKRS, NEUROD2, STARD3, TOP2A, SMARCE1, TMEM99, EIF1, NT5C3L, KLHL11, ACLY, NKIRAS2, KAT2A, COASY, MLX, EZH1, VPS25, CCDC56, BECN1, PSME3, RUNDC1, RPL27, BRCA1, NBR2, NBR1, DUSP3, TMEM101, LSM12, TMUB2, GPATCH8, CCDC43, EFTUD2, NMT1, and MAP3K14 133 In the CAPOX-B therapy cohort, loss of this region was associated with a shorter PFS (p = 0.004) Haan et al. (2014) 18p11.32 USP14, THOC1, C18orf56, TYMS, ENOSF1, and YES1 111 In the CAPIRI therapy cohort, loss of this region was associated with a longer PFS (p = 0.04) Haan et al. (2014) 18p11.32-p11.21 METTL4, NDC80, SMCHD1, EMILIN2, LPIN2, MRCL3, MRLC2, ZFP161, RAB12, KIAA0802, NDUFV2, ANKRD12, TWSG1, RALBP1, PPP4R1, VAPA, and NAPG 133 In the CAPOX-B therapy cohort, loss of this region was associated with a longer PFS (p = 0.048) Haan et al. (2014) 18p11.21 CHMP1B, MPPE1, IMPA2, TUBB6, AFG3L2, CEP76, PSMG2, PTPN2, SEH1L, CEP192, C18orf19, and RNMT 133 In the CAPOX-B therapy cohort, loss of this region was associated with a longer PFS (p = 0.039) Haan et al. (2014) 18p11.32
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Amplification was significantly associated with worse median survival in patients receiving adjuvant 5-FU based chemotherapy (HR = 2.7, p = 0.027) Watson et al. (2010) 18q11.2 Loss LAMA3 133
In the CAPOX-B therapy cohort, loss of this region was associated with a longer PFS (p = 0.014) Haan et al. (2014) 18q12.2 
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SMAD7 deletion was associated with better OS (HR = 0.43, p = 0.0012) and DFS (HR = 0.50, p = 0.0033) Boulay et al. (2003) 18q21.1
Gain SMAD7
SMAD7 duplication was associated with worse OS (HR = 2.10, p = 0.020) and DFS (HR = 2.06, p = 0.015) Boulay et al. (2003) 18q21.2 Loss SMAD4 147
Significantly associated with tumor progression (p = 0.041) Ma et al. (2014) 18q21 Loss CD226 172 Patients having CD226 deletion had a better OS when treated with 5 FU (HR = 0.51, p = 0.05), while no significant difference in OS was observed between 5-FU treated and untreated patients with CD226 retention. Patients in the control group having loss of CD226 had a worse OS (HR = 2.44, p = 0.01) and DFS (HR = 1.99, p = 0.03) Storojeva et al. (2005) (continued on next page) T. Ried, et al. Molecular Aspects of Medicine 69 (2019) 48-61 patients with metastatic CRC (mCRC) (Yokota et al., 2011) . Another prognostic marker used in the clinic, albeit it is only listed as a recommendation in the clinical guidelines, is the mismatch repair status (Sepulveda et al., 2017) . Additionally, this guideline concluded that there was insufficient evidence to recommend the following as predictive biomarkers in CRC outside of clinical trials: BRAF V600E mutation, PIK3CA mutational analysis and PTEN expression or deletion (Sepulveda et al., 2017) .
To date, there are still unmet clinical needs in certain areas of CRC management, notably for prognostication in stage II colon cancer patients, who suffer from a lack of effective stratification parameters to inform who are most likely to recur (Dimitriou et al., 2018) . In fact, the majority of current predictive biomarkers are only applied to stage IV CRC patients. Thus, many patients would benefit from improved prognostic and predictive stratification, which would also help with clinical trial design, for example in basket trials. CRC still lacks adequate predictive biomarkers compared to other cancers such as melanoma, leukemia, breast, ovarian, prostate and lung cancer (Sameek and Chinnaiyan, 2014) . As molecular cytogenetic methodologies as well as next-generation sequencing-based techniques to assess CNAs can be applied to archived formalin-fixed paraffin-embedded (FFPE) material, the analysis of large series of CRCs with well annotated clinical followup became feasible allowing the analysis of the prognostic and predictive value of CNAs. Therefore, CNAs affecting genes such as SMAD2, MYC, EGFR, STRAP, SMAD7, and SMAD4 are being investigated for prognostic or predictive significance (Briffa et al., 2015; Hu et al., 2018; Postma et al., 2009 ). Another study on the effect of CNAs in several cancers highlighted their effect on proliferation and glycolysis (Graham et al., 2017) . Despite the fact that several studies have been published on the prognostic and predictive values of CNAs in CRC, in this review we have limited our discussion to non-controversial candidate biomarkers that have been investigated in prospective clinical trials. The candidate biomarkers with their corresponding clinical relevance are summarized in Table 2 .
Prognostic biomarkers
In advanced CRC, increased EGFR copy number is associated with poor survival and might be an independent prognostic variable (Lenz et al., 2006) . With regard to PTEN, the Molecular Biomarkers Guideline for the Evaluation of Colorectal Cancer states that more rigorous studies are required for PTEN deletion to be accepted as a prognostic/predictive biomarker in CRC (Sepulveda et al., 2017) . STRAP amplification was reported in 22.8% of stage II and III CRC (n = 166) (Buess et al., 2004a) . This gene is located on chromosome 12 and encodes a serine/ threonine kinase receptor associated protein. Of interest, patients that did not receive adjuvant therapy (n = 95) showed better prognosis when STRAP was amplified. In another cohort of 354 CRC patients (stage IV, n = 240), both gain and amplification of chromosome 20q were associated with longer overall survival (OS) in mCRC patients. Amplification was observed in 7% of mCRCs, while chromosome 20q copy number gains were observed in 37% of mCRC patients. This chromosome arm harbors several CRC-related oncogenes that might explain its prognostic value, including SRC, AURKA, TPX2, and BCL2L1 (Ptashkin et al., 2017) . The authors concluded that chromosome 20q gain/amplification is an early tumorigenic event and that it is involved with distant metastases.
Another chromosome of interest in CRC is chromosome 18q, and its deletion is postulated to be a biomarker of poor prognosis (Storojeva et al., 2005) . Deletion of CD226, a gene located on chromosome 18q that encodes for a glycoprotein expressed on the surface of NK cells, platelets, monocytes and a subset of T-cells, has been shown to be a biomarker of poor prognosis for 5-year OS and disease-free survival (DFS) (n = 94) (Ptashkin et al., 2017; Wagner et al., 2017) . In the same CRC cohort (n = 97), deletion of CDH-7 copy number was a biomarker of good outcome with respect to 5-year OS and DFS. On the contrary, in Patients in the control group having loss of CADH-7 had a better OS (HR = 0.29, p = 0.01) and DFS (HR = 0.43, p = 0.03) Storojeva et al. (2005) 18q21.33-q22 Loss MYO5B, MBD1, CXXC1, C18orf24,ME2, ELAC1, SMAD4, MEX3C, MBD2, POLI, RAB27B, CCDC68, TXNL1, WDR7, FECH, NARS, ATP8B1, ALPK2, MALT1, SEC11C, LMAN1, PMAIP1, RNF152, PIGN, KIAA1468, TNFRSF11A, ZCCHC2, PHLPP, BCL2, KDSR, VPS4B, SERPINB8, TMX3, RTTN, SOCS6, C18orf55, and CNDP2 111 In the CAPIRI therapy cohort, loss of this region was associated with a longer PFS (p = 0.001) Haan et al. (2014) 19 p13.12
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Significantly associated with OS in Stage II/III tumors (p < 0.01) Xie et al. (2012) 20q11-q13.3 Gain BCL2L1, ASXL1, SRC, DNMT3B, GNAS, TOP1, AURKA, PTPRT, and NCOA3 354 Chromosome 20q gain and amplification are significantly associated with longer OS (p = 0.015; CI, 0.36-0.90), (p = 0.039; CI, 0.11-0.94), respectively Ptashkin et al. (2017) 20q11. Significantly associated with better OS in Stage III tumors (p < 0.01) Xie et al. (2012) 20q13.2 Gain CSE1L, NABC1, ZNF217, and STK15
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Chromosomal gain was associated with worse overall survival (p = 0.006) and
faster tumor progression (p = 0.012) Aust et al. (2004) CN, copy number; DFS, disease-free survival; HR, hazard ratio; MMC, mitomycin C; OS, overall survival; PFS, progression-free survival; TTP, time to progression; 5-FU, 5-fluorouracil.
T. Ried, et al. Molecular Aspects of Medicine 69 (2019) 48-61 a cohort of 147 patients, SMAD4 copy number loss was detected in 34.7% of Chinese CRC patients, was more frequent in mCRC compared to early stage CRC, and was associated with tumor progression . Boulay and colleagues reported that SMAD7 was deleted in 43% of the 264 CRC cases and amplified in 15%. In this study, patients having SMAD7 deletion had a statistically significant better OS and progression free survival (PFS). On the other hand, SMAD7 amplification was associated with a worse OS and PFS. The authors speculated that on the assumption that SMAD7 regulates TGFβ signaling, copy number amplifications antagonize cell growth arrest and apoptosis (Boulay et al., 2003) . Similarly, a multivariate analysis identified the loss of BRUNOL4 located at 18q12.2 as an independent factor associated with poor prognosis in CRC (Poulogiannis et al., 2010a) .
Recently, Lee and colleagues showed that GAEC1 (gene amplified in esophageal cancer 1), a putative oncogene located on chromosome 7 was amplified in 24.1% of the Australian CRC cohort (n = 79) (Lee et al., 2018) . Moreover, copy number gain was associated with worse prognosis due to increased tumor aggressiveness. Another prognostic CNA is SKI, located on chromosome 1 and a repressor of TGF-β signaling. In a cohort of 533 stage II and III CRC cases, SKI gene copy number could be successfully measured in 159 patients and was amplified in 10.1% (Buess et al., 2004b) . SKI amplification was associated with a worse OS and DFS as compared to patients with no copy number increase or deletions of this gene.
In 2002, a study on an early-stage CRC cohort (n = 180) investigated allelic imbalance of chromosomes 8p and 18q with respect to disease recurrence. Patients with Dukes' A stage tumors showing allelic imbalance in both chromosome arms were more likely to present with a recurrence when compared to Dukes' B patients without allelic imbalances (Zhou et al., 2002) . Focal chromosomal CNAs have also been implicated in prognosis of CRC patients. A study on 46 stage II CRC concluded that loss of 5q34 was associated with worse OS and DFS and gain of 13q.22.1 was associated with worse OS (Brosens et al., 2010) . Another study evaluated the effect of CNAs in a cohort (consisting of 89.1% MSS cases) of 302 stage II and III CRC patients with OS and progression-free survival (Xie et al., 2012) . Deletion at 10p15.3-p14 and 19p13.12 in both stages were associated with poor OS. Furthermore, deletions of 10p15.3-p14 were also significantly associated with a worse RFS. On the contrary, in stage III patients, gain of 20q was associated with better OS. At the chromosome-arm level, loss of chromosome arm 4q (Brosens et al., 2011) and gain of chromosome arm 20q (Aust et al., 2004) were associated with poor prognosis. Also, both 8q gain and 20q gain were shown to be more frequently present in metastasized tumors than in tumors without metastases (Buffart et al., 2005; Hidaka et al., 2000) .
Predictive biomarkers
Several CNAs have been associated with response to treatment in CRC. TYMS amplification was investigated in a cohort of mCRC patients treated with 5-fluorouracil (5-FU) based therapies, where it was associated with resistance to 5-FU (Watson et al., 2010) . On the contrary, copy number deletion of the negative prognostic marker CD226 is associated with better OS following 5-FU-based therapy (Storojeva et al., 2005) . Buess and colleagues reported a study on stage II and III CRC patients (n = 166) and demonstrated that STRAP amplification results in a worse response to 5-FU based therapy which was observed with the patients having a higher relapse and death rate when compared to patients without amplification (Buess et al., 2004a) . In 2008, Postma and colleagues carried out an investigation on CNA and response to capecitabine plus irinotecan (XELIRI regimen), in a cohort of treatmentnaïve mCRC patients (n = 39). This study concluded that responders showed loss of chromosomal bands 18p11.32-q11.2 and 18q12.1-q23 ). In the KRAS wild-type mCRC sub-group, only 13-17% benefit from single-agent anti-EGFR therapy (Bertotti et al., 2011) . Additionally, in this sub-group increased EGFR copy numbers are associated with improved response rates to irinotecan-cetuximab therapy and longer time to progression (Scartozzi et al., 2009 ). Metastatic CRC patients with EGFR amplifications as confirmed by FISH are more likely to respond to monoclonal antibodies targeting EGFR (Moroni et al., 2005) . In 2013, Jiang and colleagues reported a metaanalysis of 13 studies representing 1,174 mCRC patients treated with either cetuximab or panitumumab. Their results showed that EGFR copy number gains in this population were associated with improved OS and PFS (Jiang et al., 2013) .
The mechanisms to understand why KRAS amplification in mCRC may be involved in resistance to EGFR-targeted therapies has been investigated . Yaeger and colleagues hypothesized that RAS amplification in KRAS wild-type CRCs induces acquired resistance to RAF inhibitors through the formation of drug-resistant RAF dimers, although the authors recognized that more studies are required to confirm this hypothesis . MET amplification is more frequent in mCRC cases that have acquired resistance to anti-EGFR therapy compared to de novo mCRC Pietrantonio et al., 2016) . Therefore, MET may be an ideal on-treatment monitoring candidate biomarker, especially since CNAs can be detected in cfDNA (Raghav et al., 2016) .
In addition to its role in breast cancer, HER2 amplification is an emerging biomarker in advanced CRC. Sartore-Bianchi and colleagues argued that KRAS exon 2 wild-type mCRCs should be tested for HER2 amplification because, in this sub-group of patients, HER2 amplifications may indicate responses to trastuzumab and pertuzumab; however, KRAS-mutant patients may be intrinsically resistant to anti-HER2 therapy even in the presence of HER2 amplification . Therefore, the overall genetic context matters, and individual CNAs alone may not fully indicate the treatment response of a particular tumor. In fact, Corcoran and colleagues reported BRAF amplification in a BRAF V600E mutated CRC and speculated that BRAF amplification in this cohort might lead to acquired resistance to MEK and BRAF inhibitors (Corcoran et al., 2010) .
The presence of other specific CNAs has been associated with the response to treatment in mCRC. In a comprehensive analysis of CNAs in 349 tumors resected from patients participating in the CAIRO and CAIRO2 clinical trials, it was observed that specific chromosomal regions, mainly gain of 6q and loss of 18q, were associated with significant difference in progression-free survival (PFS) between treatment arms with and without irinotecan (Haan et al., 2014) . Furthermore, van Dijk and colleagues recently reported that the loss of chromosome 18q11.2-q12.1 in mCRC patients was indicative of good prognosis as these patients achieved prolonged PFS, better OS and better overall response rate when receiving becacizumab (van Dijk et al., 2018) . Similarly, Smeets and colleagues investigated the likelihood of other CNAs as candidate predictive biomarkers to guide therapy with bevacizumab in a cohort of mCRC patients . In this study, the authors took a novel approach, where initially they clustered the CNA profiles of 908 CRC patients using unsupervised hierarchical clustering, resulting in three different clusters. The first cluster was characterized by tumors having a considerable amount of somatic mutations, including tumors having POLE and POLD1 mutations and MSI classified tumors. Additionally, this cluster had only 10.2% advanced CRC patients and presented with few CNAs when compared with the other clusters. The authors proceeded with analyzing the response of the mCRC cohort with respect to chemotherapy alone versus chemotherapy in combination with bevacizumab. Patients in cluster 2 and 3 (intermediate to high instability) being administered chemotherapy in combination with bevacizumab had a better PFS and OS when compared to those receiving chemotherapy alone. On the other hand, patients in cluster 1 did not benefit from the addition of bevacizumab. The authors proceeded with comparing the CNA-based clusters to the current CMS classification system. CNA-based clusters overlapped with CMS sub-types: cluster 1 (low CNAs) was akin to CMS1 T. Ried, et al. Molecular Aspects of Medicine 69 (2019) 48-61 and 3, cluster 2 and 3 were similar to CMS 2 and 4. As a result, it was concluded that in mCRC patients, copy number load might be a novel predictive marker for the efficacy of bevacizumab combination therapy. Besides gene dosage alterations, CIN can also lead to structural rearrangements, like breakpoints and translocations leading to fusions of different genes. Kloosterman and collegaues, in a systematic analysis of 278 CRCs, identified several novel oncogenic gene fusions in CRC that may drive malignant development and offer new targets for personalized therapy (Kloosterman et al., 2017) . Chromosomal breakpoints in MACROD2, leading to loss of its expression, occurs frequently in advanced CRC (van den Broek et al., 2015) . In addition, loss of expression of MACROD2 was associated with poor prognosis in stage II and III CRCs and with poor response to 5FU-based chemotherapy in stage III CRCs (van den Broek et al., 2018).
Conclusions and future challenges
There is a positive correlation between genomic CNAs and resident gene expression levels in cancer, resulting in a massive deregulation affecting not only genes on aneuploid chromosomes but also genes throughout the genome. This phenomenon is, naturally, associated with the fact that CNAs are cancer-type specific, which defines aneuploidydependent cancer type transcriptional programs. Taking this into consideration, several questions arise: (i) are all genes residing on a chromosome affected by such positive correlation or, alternatively, some genes escape this dependency? (ii) to what extent are CNAs the result of positively selected regions of the genome containing oncogenes and tumor suppressor genes? (iii) are those gene expression networks defined in carcinomas already functional in premalignant lesions? It remains to be clarified how exactly aneuploidy shapes the transcriptome of cancer cells and why cancer cells require such aneuploidy-specific deregulated transcriptional networks.
From the clinical point of view, the translational significance of genomic CNAs into clinical practice requires further studies. Eventually, understanding CNAs will allow stratification of patients based on biological and genetic features to improve disease prognostication, follow-up and to guide therapeutic strategies.
Conflicts of interest
The authors declare no conflicts of interest.
